CTLA4 and melanoma: The Allen cohort (14) included 72 patients with melanoma treated with anti-CTLA-4, among whom six patients were classified as CCND1 amplification; their disease-free survival (DFS) was inferior to that of 66 patients with the neutral phenotype [2.667 vs. 3.233 months, P = 0.1196, HR 2.001 (95% CI 0.5786–6.922); Figure S1C].